A Clinical Experience with Neurofilament Light Chain as a Biomarker in ALS: Ready for Use as Inclusion Criteria for Clinical Trials? (P11-11.022)
To explore the potential utility of serum neurofilament light chain (NFL) as inclusion criteria for clinical trials in patients with amyotrophic lateral sclerosis (ALS).
Authors
- Jeffrey Mullen
- Namita Goyal (ORCID: https://orcid.org/0000-0002-1713-545X)
- Tahseen Mozaffar (ORCID: https://orcid.org/0000-0002-1230-0188)
- Dennis S. Huang
- Ali A. Habib (ORCID: https://orcid.org/0000-0003-3432-9747)
Institutions
- University of California, Irvine (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212135
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00